Freising (ots) – Pieris AG announced today that Stephen Yoder, Chief Executive Officer, is scheduled to present at the 18th Annual BioCentury Future Leaders in the Biotech Industry Conference 2011, to be held Friday, April 15, 2011 at the Millennium Broadway Hotel & Conference Center in New York, New York. Mr. Yoder and Dr. Laurent [...]
Tag Archive > Sny
Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics
Freising-Weihenstephan (ots) – Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), under which Pieris will apply its proprietary Anticalin technology to discover novel Anticalin drugs against multiple targets, with further development undertaken by [...]
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Paris, November 30 (ots/PRNewswire) – – First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone – 400mg Tablets) in all 27 European member states. This approval follows the European [...]
Sanofi-aventis startet neues großes Register mit über 10.000 Vorhofflimmer-Patienten weltweit
Paris, Frankreich – 16. November 2009 – (ots) – Das RealiseAF-Register wird dazu beitragen, das kardiovaskuläre Risikoprofil von Vorhofflimmerpatienten besser zu definieren und zu verstehen sowie kardiovaskuläre Folgen besser zu charakterisieren Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) gab heute den Start des RealiseAF-Registers bekannt (Real life global Survey Evaluating patients with Atrial Fibrillation), einem internationalen [...]
Sanofi-aventis Launches Major New Registry Including Over 10,000 Patients Worldwide With Atrial Fibrillation
Paris, November 16 (ots/PRNewswire) – – The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the launch of the RealiseAF registry (Real Life global Survey Evaluating patients with Atrial Fibrillation), an international, cross-sectional, observational [...]
Superior Efficacy-dose Ratio for Lantus(R) Over detemir
Paris (ots/PRNewswire) – – 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R) Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir. The [...]
Sanofi Aventis : Multaq(R) (dronedarone) Recommended for Approval in the European Union
Paris (ots/PRNewswire) – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone – 400mg Tablets). The CHMP has recommended the approval of [...]
FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter
Paris (ots/PRNewswire) – – Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter – U.S Commercial Launch Planned for the Summer of 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients [...]
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Paris and Brisbane, California (ots/PRNewswire) – – Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with [...]
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial With Multaq(R) (dronedarone) in Atrial Fibrillation
Paris (ots/PRNewswire) – – Multaq(R) (dronedarone) Significantly Reduced the Risk of Cardiovascular Hospitalization or Death by 24 Percent in Patients With Atrial Fibrillation Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) announced today that the ATHENA trial was published in the New England Journal of Medicine. The trial showed that Multaq(R) (dronedarone), in [...]
New England Journal of Medicine veröffentlicht Ergebnisse der Meilensteinstudie ATHENA mit Dronedaron bei Vorhofflimmern
Paris, Frankreich (ots) – – Dronedaron reduziert das Risiko für kardiovaskulär bedingte Krankenhausaufenthalte oder Tod bei Patienten mit Vorhofflimmern signifikant um 24 Prozent – Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) gab heute bekannt, dass die ATHENA Studie im New England Journal of Medicine publiziert wurde. Die Studie zeigt, dass Dronedaron (Multaq®) [...]
